The privately held company has developed a pipeline of agents that target CD44 and have demonstrated anti-angiogenic and anti-metastatic activity, as well as synergistic cytotoxicity with other chemotherapy agents. Splash is actively seeking Pharma partners to accelerate its clinical programs. Its lead therapy has completed multiple Phase I and II clinical trials with promising results, and the company aims to provide dramatic and durable responses in many solid tumors.